<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37672770</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1734-154X</ISSN><JournalIssue CitedMedium="Internet"><Volume>70</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Sep</Month><Day>06</Day></PubDate></JournalIssue><Title>Acta biochimica Polonica</Title><ISOAbbreviation>Acta Biochim Pol</ISOAbbreviation></Journal><ArticleTitle>CRISPR-Cas9 guided rna based model for the treatment of Amyotrophic Lateral Sclerosis: A progressive neurodegenerative disorder.</ArticleTitle><Pagination><StartPage>643</StartPage><EndPage>653</EndPage><MedlinePgn>643-653</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.18388/abp.2020_6789</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder that leads to the degeneration of motor neurons and the weakening of muscles. Despite extensive research efforts, there is currently no cure for ALS and existing treatments only address its symptoms. To address this unmet medical need, genome editing technologies, such as CRISPR-Cas9, have emerged as a promising solution for the development of new treatments for ALS. Studies have shown that CRISPR-Cas9-guided RNAs have the potential to provide accurate and effective silencing in the genetic disease of ALS. Results have demonstrated a 67% on-target score and a 98% off-target score with GC content within the range of 40-60%. This is further validated by the correlation between the gRNA's structural accuracy and the minimum free energy. The use of CRISPR-Cas9 provides a unique opportunity to target this disease at the molecular level, offering hope for the development of a more effective treatment. In silico and computational therapeutic approaches for ALS suggest that the CRISPR-Cas9 protein holds promise as a future treatment candidate. The CRISPR mechanism and the specificity of gRNA provide a novel therapeutic approach for this genetic disease, offering new hope to those affected by ALS. This study highlights the potential of CRISPR-Cas9 as a promising solution for the development of new treatments for ALS. Further research is required to validate these findings in preclinical and clinical trials and to establish the safety and efficacy of this approach in the treatment of ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Naveed</LastName><ForeName>Muhammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biotechnology, Faculty of Science and Technology, University of Central Punjab, Lahore Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aqib Shabbir</LastName><ForeName>Muhammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biotechnology, Faculty of Science and Technology, University of Central Punjab, Lahore Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aziz</LastName><ForeName>Tariq</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Agriculture University of Ioannina Arta 47100 Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hurraira</LastName><ForeName>Hafiz Muhammad</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Department of Biotechnology, Faculty of Science and Technology, University of Central Punjab, Lahore Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fatima Zaidi</LastName><ForeName>Sayyeda</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biotechnology, Faculty of Science and Technology, University of Central Punjab, Lahore Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Athar</LastName><ForeName>Ramsha</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Biotechnology, Faculty of Science and Technology, University of Central Punjab, Lahore Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chattha</LastName><ForeName>Hassan Anwer</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>Department of Biotechnology, Faculty of Science and Technology, University of Central Punjab, Lahore Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alharbi</LastName><ForeName>Metab</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alshammari</LastName><ForeName>Abdulrahman</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alasmari</LastName><ForeName>Abdullah F</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Poland</Country><MedlineTA>Acta Biochim Pol</MedlineTA><NlmUniqueID>14520300R</NlmUniqueID><ISSNLinking>0001-527X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000094704">RNA, Guide, CRISPR-Cas Systems</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064113" MajorTopicYN="N">CRISPR-Cas Systems</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072669" MajorTopicYN="N">Gene Editing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009132" MajorTopicYN="N">Muscles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094704" MajorTopicYN="N">RNA, Guide, CRISPR-Cas Systems</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>6</Day><Hour>18</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>6</Day><Hour>17</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37672770</ArticleId><ArticleId IdType="doi">10.18388/abp.2020_6789</ArticleId><ArticleId IdType="pii">6789</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>